Why Customer's Stickiness Is The Real Growth Engine Behind Celestica

Celestica (CLS) is rated a buy on accelerating revenue and profit growth driven by customized solutions across Advanced Technology Solutions (ATS) and Connectivity & Cloud Solutions (CCS), notably AI-related HPS products that underpin leadership in AI/ML infrastructure. The thesis cites improved leverage and capital efficiency, ATS focus on complex high-margin projects and customer stickiness in CCS/HPS as drivers of margin expansion, while noting risks from low overall margins and customer concentration; despite valuation concerns, CLS is presented as undervalued versus peers given superior growth, profitability and ROIC.

Analysis

Market structure: Celestica (CLS) is a beneficiary of rising AI/ML infrastructure demand where customized, high-complexity ATS and HPS systems create sticky revenue and higher ASPs. Winners include CLS, specialist EMS peers with AI stacks, and component suppliers (high-performance GPUs, power subsystems); losers are low-end, volume-focused EMS providers that compete on price. Expect incremental pricing power for complex builds: 5–10% higher gross margins over 12–24 months versus legacy business if HPS ramps as guided.

Risk assessment: Key tail risks are loss of a top hyperscaler customer (could cut revenues by ~15–25% for a concentrated EMS) and component shortages or sudden GPU pricing declines that compress ASPs by 200–400 bps; regulatory/geo-political export controls on AI chips would be high-impact. Near-term (days–weeks) volatility will hinge on quarterly guidance; medium-term (3–12 months) outcome depends on contract wins and backlog conversion; long-term (2–5 years) hinges on CLS turning AI solutions into sustained 15–20%+ incremental ROIC.

Trade implications: Establish a concentrated long bias to CLS ahead of the next two quarters where AI HPS revenue could show material acceleration. Use pair trades: long CLS vs short FLEX or JBL to express structural premium for complex builds. Options: accumulate via 6–12 month LEAPs or sell 30-delta puts to lower basis; take profits or hedge if CLS rallies >25% in 60 days.

Contrarian angles: Consensus may underprice customer concentration and margin cyclicality — upside requires visible multi-quarter contract renewals rather than single-quarter beats. Reaction could be underdone if guidance confirms multi-year HPS contracts, but overdone if market misinterprets short-term inventory digestion as demand weakness. Watch historic EMS rebounds (post-2016 cycles) where leadership in niche systems captured outsized share; absence of diversified end-market demand is the main unintended risk.

Key Decisions for Investors

• Consider establishing a 2–3% long position in CLS (shares) within 2–6 weeks, scaling in on any pullback >5%; set a tactical stop-loss at -20% and take partial profits if position rises +25% within 90 days.
• If you prefer leverage, buy 9–15 month LEAP calls on CLS (e.g., Jan 2026 expiries) sized to equal 1–1.5% portfolio delta exposure to capture multi-quarter AI HPS ramp; trim if CLS reports sequential margin decline >200 bps or guidance misses by >5%.
• Implement a pair trade: long CLS (1.5–2% net exposure) and short FLEX (FLEX) or Jabil (JBL) (1.0–1.5%) for 6–12 months to capture relative outperformance driven by AI-customized systems; exit if spread reverses >10% or CLS guidance disappoints.
• Use an income-accumulation tactic: sell 30-delta 3–6 month puts on CLS to collect premium and acquire stock below current levels; target strikes ~8–12% below entry price and cap assignment exposure to 3% of portfolio.